Recovery from addiction is a challenging journey, filled with both triumphs and setbacks. For individuals seeking long-term sobriety, relapse can be a disheartening reality. However, recent findings ...
Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo CAPLYTA ® is FDA approved to treat schizophrenia ...